These findings correspond to enhanced production of CIT- and MAA-modified lung autoantigens as well as generation of anti-MAA antibody (but not anti-HSA-CIT/ACPA), suggesting a potential role for MAA-targeted immune responses in the development of inflammatory lung disease with and without concomitant RA. This evidence concerns the gene PRTN3 and rheumatoid arthritis.